Short-Term Debt to Equity Ratio: Amylyx Pharmaceuticals (AMLX)
Amylyx Pharmaceuticals (AMLX) faces liquidity threats due to a limited drug portfolio and uncertainty regarding insurance reimbursements. R&D is currently undergoing a radical transformation following the failure of its primary product, focusing instead on the discovery of new molecules. This price chart reflects a metric at 0.00. Amylyx Pharmaceuticals (AMLX) aims to lead the dementia therapy segment by developing agents to protect brain cells from degradation.
Analytical breakdowns for Amylyx Pharmaceuticals
- stock quotes and analyst forecast:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- company liabilities and liquidity data:
Total Debt to Capital Amylyx Pharmaceuticals|AMLX - Long-Term Debt to Capital|Short-Term Debt to Equity Amylyx Pharmaceuticals, Inc.|AMLX - Company Total Debt|Debt to Book Value Amylyx Pharmaceuticals Inc|AMLX - Long-Term Debt|Company Short-Term Debt Amylyx Pharmaceuticals|Quick Liquidity Indicator amylyx.com
- company profitability and valuation multiples indicators:
Fundamental company analysis:Amylyx AMLX
To implement its strategy for expanding its portfolio of drugs against rare neurological pathologies, Amylyx Pharmaceuticals (AMLX) requires precise liquidity management when acquiring new molecules. By analyzing the dynamics of the ratio between short-term liabilities and equity, the investor assesses the share of short-term obligations within the equity structure, where a decreasing coefficient confirms financial stability, while an increase signals risky leverage for operational scaling.
Competitors of Amylyx Pharmaceuticals (AMLX)
Short-Term Debt to Capital BIIB|NBIX - Current Liabilities to Capital|Regencell Bioscience - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital axsome.com AXSM|ACAD - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital XENE (Xenon Pharmaceuticals Inc.)|Viking Pharma (VKTX) - Short-Term Debt to Equity|Current Liabilities to Capital Supernus Corp (SUPN)|CPRX (Catalyst Pharmaceuticals) - Short-Term Debt to Capital|Short-Term Debt to Capital denalitherapeutics.com|Short-Term Debt to Equity Harmony Biosciences Holdings, Inc. (HRMY)|Short-Term Debt to Equity Ratio Biohaven Ltd BHVN|Trevi Pharma - Short-Term Debt to Equity Ratio|Praxis Corp (PRAX) - Current Liabilities to Capital|AVXL - Short-Term Debt to Equity|CBLL: Short-Term Debt to Equity|PRTA (Prothena Corp) - Short-Term Debt to Equity Ratio|Current Liabilities to Capital Alector (ALEC)|Short-Term Debt to Equity Ratio ANNX|Short-Term Debt to Capital Ratio OMER (Omeros Corp.)|Short-Term Debt to Equity Ratio NGNE (Neurogene Inc.)|ACIU (acimmune.com) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Voyager Therapeutics, Inc. VYGR|NMRA (Neumora) - Current Liabilities to Equity|Scilex Holding Co. - Short-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital TVGN (Tevogen Bio Inc.)|ACOG: Short-Term Debt to Capital|cogrx.com (CGTX) - Short-Term Debt to Capital|Short-Term Debt to Equity Inhibikase Therapeutics, Inc.|SAVA: Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Assertio Holdings, Inc. (ASRT)|Short-Term Debt to Equity Ratio coyatherapeutics.com COYA|Short-Term Debt to Capital VTGN (Vistagen)|Short-Term Debt to Capital Ovid Therapeutics Inc OVID|Acumen Pharmaceuticals, Inc. - Short-Term Debt to Capital|CervoMed, Inc. (CRVO) - Short-Term Debt to Equity Ratio|ATHE: Short-Term Debt to Capital|Current Liabilities to Capital Clene (CLNN)|Short-Term Debt to Equity Ratio PEPG|Short-Term Debt to Capital jupiterneurosciences.com|Short-Term Debt to Equity Ratio RLMD (Relmada Therapeutics, Inc.)|Short-Term Loans to Capital Ratio ANVS|Short-Term Debt to Capital GRCE (Grace Therapeutics)|Short-Term Debt to Capital Coefficient Firefly Neuro (AIFF)|ANEW Medical, Inc. - Short-Term Debt to Capital|NeuroSense Therapeutics (NRSN) - Short-Term Debt to Equity Ratio|RVPH: Short-Term Debt to Capital|MetaVia (MTVA) - Short-Term Debt to Capital|Short-Term Debt to Equity NeurAxis, Inc|Short-Term Debt to Equity HSDT|Short-Term Debt to Equity Passage Bio, Inc. (PASG)|Short-Term Debt to Capital Coefficient bionomics.com.au|Short-Term Debt to Capital NERV (Minerva Neurosciences, Inc.)|Short-Term Debt to Capital Athira Pharma Inc ATHA|ADXN - Short-Term Debt to Equity|Alzamend Neuro, Inc. (ALZN) - Short-Term Debt to Equity Ratio|cyclerion.com (CYCN) - Short-Term Debt to Equity|PTIX (Protagenic Therapeutics, Inc.) - Short-Term Debt to Equity|Short-Term Debt to Equity Ratio KTTA|Short-Term Debt to Capital Ratio CRGT (Cortigent Medical)|Short-Term Debt to Equity Avenue Therapeutics, Inc (ATXI)|BrainStorm Cell Therapeutics Inc. - Short-Term Debt to Capital Ratio|Short-Term Debt to Capital CARA (Cara Therapeutics, Inc.)|chromocell.com (CHRO) - Current Liabilities to Capital|ELYM: Short-Term Debt to Equity Ratio|ITCI - Short-Term Debt to Capital|Longboard Pharma (LBPH) - Short-Term Debt to Equity|Marinus Pharma - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity NKGen Biotech, Inc.|Current Liabilities to Capital neurobopharma.com NRBO|Short-Term Debt to Capital SAGE|Short-Term Debt to Capital Synaptogenix Inc. (SNPX)|Short-Term Debt to Equity Trevena, Inc TRVN|VIGL - Short-Term Debt to Equity Ratio|WENA: Short-Term Debt to Equity Ratio|Current Liabilities to Capital cerevel.com